Somatropin: A Literature Course

This page is for educational purposes only and is not medical advice; consult a licensed physician about any medical question or any decision involving a prescription product. Nothing here describes a protocol, and no outcome described below should be read as a promise of benefit. The purpose of this course is to summarise what published studies of somatropin actually measured and what researchers reported.

Module 1 — What Somatropin Is and How It Has Been Studied

Somatropin is the international nonproprietary name for recombinant human growth hormone (rhGH): a 191-amino-acid single-chain polypeptide manufactured by recombinant DNA technology so that its sequence corresponds to pituitary-derived human growth hormone. It is a protein hormone rather than a small molecule, and because it is degraded in the gut it has been studied exclusively as an injected preparation in the clinical literature.

Class and origin

In the trial literature somatropin functions as the reference or comparator agent for growth hormone replacement. Branded daily somatropin products have served as the active control arm in modern registration studies — for example, a phase 3 study in Japanese children with growth hormone deficiency compared once-weekly somatrogon with once-daily Genotropin, a somatropin product (PMID 35417909). A global phase 3 trial likewise randomised children with growth hormone deficiency to weekly somatrogon or daily somatropin (PMID 35405011).

Forms described in the literature

Two broad categories appear across the studies in this course. The first is conventional daily somatropin, given as a subcutaneous injection. The second is long-acting derivatives engineered to extend exposure: somatrogon, a fusion protein reviewed in the paediatric endocrinology literature (PMID 40049670), and lonapegsomatropin, a prodrug that releases unmodified somatropin and which received a paediatric first approval described in a 2022 drug profile (PMID 34709591). These are not somatropin itself; they are distinct molecules studied against it.

Populations studied

Studies have enrolled treatment-naïve prepubertal children with growth hormone deficiency (PMID 34272849), children already established on daily somatropin who were switched to a weekly agent (PMID 35263755), adults with growth hormone deficiency (PMID 41420532), and young people in the transition phase who had been treated with somatropin during childhood (PMID 36155741).

Limits of the evidence in this module: the definitional literature describes somatropin in the context of diagnosed growth hormone deficiency and related approved indications. The verified studies here do not characterise somatropin in healthy adults, in athletic settings, or for anti-ageing purposes, and no conclusion about those uses can be drawn from them.

Module 2 — Mechanism as Described in the Literature

Somatropin is described in these papers as replacement for endogenous growth hormone, and the trials that use it are built around that premise rather than around novel mechanistic discovery. The standard framework in the cited reports is that growth hormone acts at the growth hormone receptor and drives hepatic and peripheral production of insulin-like growth factor 1 (IGF-1), which is why IGF-1 standard deviation scores are tracked as a pharmacodynamic readout.

That readout is visible directly in the trial design. The heiGHt trial in treatment-naïve children reported IGF-1 responses alongside growth outcomes for weekly lonapegsomatropin and daily somatropin (PMID 34272849), and the review of somatrogon trials likewise discusses IGF-1 behaviour as part of the comparison between weekly and daily growth hormone exposure (PMID 40049670).

Why long-acting forms exist

The mechanistic rationale for the weekly agents, as stated in their publications, is reduction of injection frequency while maintaining growth hormone receptor activation across the week. Lonapegsomatropin is characterised as a prodrug designed to release unmodified somatropin (PMID 34709591), whereas somatrogon achieves extended exposure through protein engineering as summarised in its clinical-trial review (PMID 40049670).

Downstream endpoints used as mechanism proxies

• Annualised height velocity and height standard deviation score in children (PMID 35405011).
• Body composition, specifically trunk percent fat, in adults with growth hormone deficiency (PMID 41420532).
• Bone mass and osteometabolic markers in individuals treated with somatropin during childhood and assessed in the transition phase (PMID 36155741).

Limits of the evidence in this module: mechanism in these papers is inferred from clinical biomarkers, not from receptor-level experiments conducted within the trials. None of the verified studies performed mechanistic work in cell or animal models, so the receptor and IGF-1 framework is context carried in from prior literature rather than something these particular studies tested.

Module 3 — Reported Outcomes by Study

The table below summarises the design and reported endpoints of the principal comparative studies. No result should be read as generalising beyond the population and duration studied.

Children

In the global phase 3 comparison, researchers evaluated once-weekly somatrogon against once-daily somatropin in children with growth hormone deficiency and reported height velocity as the efficacy measure alongside safety data (PMID 35405011). A parallel randomised phase 3 study conducted in Japanese children applied the same comparison against once-daily Genotropin and reported efficacy and safety outcomes for that population (PMID 35417909). The heiGHt trial applied an analogous design with lonapegsomatropin in treatment-naïve children and reported annualised height velocity against daily somatropin (PMID 34272849).

Switching and long-term follow-up

The fliGHt trial specifically studied children who moved from daily somatropin to weekly lonapegsomatropin and reported on the safety and growth outcomes of that transition (PMID 35263755). An open-label nine-year extension of a phase 2 study followed children receiving once-weekly somatrogon and reported long-term growth and safety observations (PMID 42372104).

Adults

The foresiGHt trial evaluated once-weekly lonapegsomatropin in adults with growth hormone deficiency, with body composition as the reported efficacy focus (PMID 41420532). Separately, an Italian observational report described somatropin therapy in adults with growth hormone deficiency in routine practice (PMID 35241041).

Bone and metabolic endpoints after childhood treatment

A Brazilian study examined osteometabolic profile and bone mass during the transition phase in individuals treated with somatropin during childhood and analysed ethnic differences within that cohort (PMID 36155741).

Clinician-reported experience

A cross-sectional survey of physicians involved in the global phase 3 study reported their experience with a once-weekly somatrogon regimen compared with a once-daily rhGH regimen in paediatric patients (PMID 37955005). This is an experience survey, not an efficacy measurement.

Limits of the evidence in this module: most of these trials were designed to test whether a weekly analogue performed acceptably relative to daily somatropin, so somatropin appears as a benchmark rather than as the investigational agent. Endpoints were height velocity, body composition and safety over defined periods; adult height, quality-of-life durability and cardiovascular outcomes were not the primary questions. Findings in growth hormone-deficient populations do not transfer to people with normal growth hormone secretion.

Module 4 — Somatropin Side Effects: What Studies Report

Adverse events in this literature are reported at the trial level, usually in pooled safety summaries rather than as individual symptom narratives. The following reflects what the cited publications state.

Comparative trial safety reporting

The global phase 3 study of weekly somatrogon versus daily somatropin in children reported safety alongside efficacy as a co-equal objective of the trial (PMID 35405011), and the Japanese randomised phase 3 study similarly reported efficacy and safety for weekly somatrogon against once-daily Genotropin (PMID 35417909). The heiGHt trial reported safety outcomes for treatment-naïve children receiving weekly lonapegsomatropin or daily somatropin (PMID 34272849).

Switching and long-term safety

In the fliGHt trial, safety was a stated focus for children switching from daily somatropin to weekly lonapegsomatropin (PMID 35263755). The nine-year open-label extension of once-weekly somatrogon reported long-term safety observations in children with growth hormone deficiency (PMID 42372104), and a comprehensive review of somatrogon trials collated safety findings across the programme together with real-world considerations (PMID 40049670).

Adults

In adults with growth hormone deficiency, the foresiGHt trial reported safety alongside its body-composition efficacy endpoints for once-weekly lonapegsomatropin (PMID 41420532), and the Italian report described somatropin therapy in adults in a real-world clinical context (PMID 35241041).

A separate risk described in the literature: product authenticity

One study addressed a risk unrelated to pharmacology. Researchers assessed the availability and quality of illegitimate somatropin products obtained from the internet and reported on what those products actually contained (PMID 27888454). That report concerns product integrity outside regulated supply chains rather than the safety profile of an approved prescription medicine.

Limits of the evidence in this module: the abstracts summarised here report that safety was assessed and characterise it at a high level; this page does not reproduce event-by-event incidence figures because they are not within the abstract scope of the verified sources. Trials also enrolled defined diagnostic populations under monitoring, which constrains how their safety observations should be interpreted. Rare events and outcomes beyond the follow-up periods studied would not necessarily be captured.

Module 5 — Pharmacokinetics Where Data Exist

The defining pharmacokinetic feature of somatropin in this literature is its short duration of action, which is the reason daily subcutaneous administration was the established regimen and the reason long-acting alternatives were developed and tested against it (PMID 40049670).

The engineering strategies differ. Lonapegsomatropin is described as a prodrug that releases unmodified somatropin, an approach summarised in its first-approval profile (PMID 34709591); somatrogon is a long-acting growth hormone reviewed across its clinical trial programme (PMID 40049670). Both were then tested at weekly dosing intervals against daily somatropin in randomised trials (PMID 35405011, PMID 34272849).

Pharmacodynamically, IGF-1 was used as the exposure-linked biomarker in these programmes, including in treatment-naïve children (PMID 34272849) and in the switching population studied in fliGHt (PMID 35263755).

Limits of the evidence in this module: the verified sources are efficacy and safety trials, reviews and approval profiles, not dedicated pharmacokinetic studies. Specific half-life values, clearance parameters, bioavailability percentages and milligram-per-kilogram exposure figures are outside the scope of these abstracts and are therefore not stated here. Pharmacokinetics also vary with body weight, age and formulation, none of which these sources resolve at the individual level.

Module 6 — Regulatory Status

Somatropin is a prescription biologic. Multiple somatropin products are approved for growth hormone deficiency and related indications and are marketed under brand names; Genotropin, for example, served as the approved daily comparator in a randomised phase 3 study in Japanese children (PMID 35417909). Long-acting analogues have followed their own regulatory pathways: lonapegsomatropin received a paediatric first approval, as documented in a 2022 drug profile (PMID 34709591), and somatrogon's development and regulatory trajectory are summarised in a review of its clinical trials and real-world considerations (PMID 40049670).

Research-use-only material and unregulated supply

Material labelled "research use only" is not an approved medicine, is not intended for human administration, and is not manufactured to pharmaceutical standards. The literature contains a directly relevant cautionary dataset: researchers examined illegitimate somatropin products obtained over the internet and reported on their availability and quality (PMID 27888454). Regulated approval pathways exist in part because identity, potency and sterility cannot be assumed outside them.

Compounding

Compounding of a drug that is essentially a copy of a commercially available approved product is generally restricted under United States compounding law, and somatropin exists as multiple approved commercial products. This is a factual description of how the regulatory framework operates and is not legal advice; regulatory status also differs by country and can change.

Limits of the evidence in this module: approval status is jurisdiction-specific and time-specific. The cited approval profile and review describe regulatory events at the time of publication and do not reflect subsequent changes, label expansions or withdrawals in any given country.

What the Studies Did Not Test

Across the verified literature, several questions were never addressed:

• Healthy individuals. The trials enrolled people with diagnosed growth hormone deficiency (PMID 35405011, PMID 41420532). None evaluated somatropin in people with normal growth hormone secretion.
• Performance, physique or anti-ageing use. No verified study examined these contexts or their risks.
• Unsupervised or non-prescription use. The only source touching unregulated supply assessed product quality, not clinical outcomes (PMID 27888454).
• Lifetime outcomes. Even the longest follow-up here is a nine-year open-label extension in children (PMID 42372104); decades-long mortality and cardiovascular endpoints were not the question.
• Combination with other compounds. No verified study tested somatropin alongside other peptides or hormones.

Readers comparing modules should note that much of what is commonly attributed to somatropin in general discussion is not what these specific studies measured. The literature summarised here is narrow, clinical, and tied to defined deficiency populations.

References

• Efficacy and Safety of Weekly Somatrogon vs Daily Somatropin in Children With Growth Hormone Deficiency: A Phase 3 Study (The Journal of Clinical Endocrinology and Metabolism, 2022)
• Weekly Lonapegsomatropin in Treatment-Naïve Children With Growth Hormone Deficiency: The Phase 3 heiGHt Trial (The Journal of Clinical Endocrinology and Metabolism, 2021)
• Efficacy and Safety of Once-Weekly Lonapegsomatropin in Adults With Growth Hormone Deficiency: foresiGHt Trial Results (The Journal of Clinical Endocrinology and Metabolism, 2026)
• Lonapegsomatropin: Pediatric First Approval (Paediatric Drugs, 2022)
• Somatrogon in pediatric growth hormone deficiency: a comprehensive review of clinical trials and real-world considerations (Annals of Pediatric Endocrinology & Metabolism, 2025)
• Somatropin therapy in Italian adults with growth hormone deficiency (BMC Endocrine Disorders, 2022)
• Open-Label 9-Year Follow-Up Extension Phase 2 Study of Once-Weekly Somatrogon in Children With Growth Hormone Deficiency (The Journal of Clinical Endocrinology and Metabolism, 2026)
• Osteometabolic profile and bone mass in the transition phase: ethnic differences in Brazilians treated with somatropin during childhood (Jornal de Pediatria, 2023)
• Efficacy and Safety of Once-Weekly Somatrogon Compared with Once-Daily Somatropin (Genotropin) in Japanese Children with Pediatric Growth Hormone Deficiency: Results from a Randomized Phase 3 Study (Hormone Research in Paediatrics, 2022)
• Physician experience with once-weekly somatrogon versus once-daily rhGH regimen in pediatric patients with growth hormone deficiency: a cross-sectional survey of physicians from the global phase 3 study (Frontiers in Endocrinology, 2023)
• Switching to Weekly Lonapegsomatropin from Daily Somatropin in Children with Growth Hormone Deficiency: The fliGHt Trial (Hormone Research in Paediatrics, 2022)
• Availability and quality of illegitimate somatropin products obtained from the Internet (International Journal of Clinical Pharmacy, 2017)